The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - enGene
Stock and Other Ownership Interests - enGene
A phase 1/2 study of EG-70 (detalimogene voraplasmid) intravesical monotherapy for patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
 
Richard Bryce
Employment - enGene; Rain Oncology
Stock and Other Ownership Interests - enGene; Rain Oncology
 
Christine Tosone
Employment - enGene
Stock and Other Ownership Interests - enGene
 
James C. Sullivan
Employment - enGene
Stock and Other Ownership Interests - enGene
 
Tammy Linback
No Relationships to Disclose
 
Gary D. Steinberg
Stock and Other Ownership Interests - CG Oncology; enGene; Epivax Therapeutics
Honoraria - Aduro Biotech; AstraZeneca; Bristol-Myers Squibb; CG Oncology; enGene; Epivax Oncology; fergene; Ferring; Fidia Farmaceutici S. p. A.; FKD Therapies; Janssen Oncology; MDxHealth; Merck; Pfizer; Photocure; Roche/Genentech; Seagen; Sesen Bio; Urogen pharma
Consulting or Advisory Role - Asieris Pharmaceuticals; AstraZeneca; Aura Biosciences; Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; Imvax; MDxHealth; Merck; NanOlogy; Natera; Nonagen Bioscience; photocure; Roche/Genentech; Taris BioMedical; Verity Pharmaceuticals